Adam J Lamble
Overview
Explore the profile of Adam J Lamble including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair M, Silbert S, Rejeski K, Wilson K, Lamble A, Lamble A, et al.
Blood
. 2024 Nov;
145(11):1136-1148.
PMID: 39561284
Immune effector cell-associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. Although ICAHT incidence and severity is documented in large B-cell lymphoma (LBCL), mantle...
2.
Annesley C, Lamble A, Summers C, Pulsipher M, Wayne A, Rivers J, et al.
Blood Adv
. 2024 Aug;
PMID: 39133891
Infants with B-cell acute lymphoblastic leukemia (B-ALL) continue to have significantly worse outcomes compared to older children with B-ALL, and those with relapsed or refractory (R/R) infant ALL have especially...
3.
Hall A, Duenas D, Voutsinas J, Wu Q, Lamble A, Gruber E, et al.
JNCI Cancer Spectr
. 2024 Jul;
8(4).
PMID: 39078720
Background: Receipt of chimeric antigen receptor T-cell (CAR-T) therapy at an institution different from the primary oncologist's institution is a complex, multistep process. Referral by oncologists plays an important role...
4.
Lamble A, Kovach A, Shah N
Blood
. 2024 Jul;
145(1):64-74.
PMID: 39046821
Despite significant advancements in single-antigen targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL), nonresponse and relapse persist as major challenges. Antigen escape after blinatumomab or CD19-directed chimeric antigen receptor (CAR)...
5.
Lamble A, Schultz L, Nguyen K, Hsieh E, McNerney K, Rouce R, et al.
Blood Adv
. 2024 May;
8(13):3544-3548.
PMID: 38701425
No abstract available.
6.
7.
Lamble A, Moskop A, Pulsipher M, Maude S, Summers C, Annesley C, et al.
Transplant Cell Ther
. 2023 Sep;
29(11):674-684.
PMID: 37689393
Although CD19-directed chimeric antigen receptor (CAR) T cell therapy (CAR-T) for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) has been transformative in inducing and sustaining remission, relapse rates remain unacceptably...
8.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, et al.
Leukemia
. 2023 Jul;
37(9):1767-1778.
PMID: 37452102
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous system. Though more common...
9.
Schultz L, Jacoby E, Lamble A, Maude S, McNerney K, Moskop A, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):592-593.
PMID: 37442348
No abstract available.
10.
Ohlsen T, Rudzinski E, Bohling S, Liu Y, Maloney E, Lindberg A, et al.
J Pediatr Hematol Oncol
. 2023 Apr;
45(5):e635-e638.
PMID: 37027334
Ewing sarcoma is a small round blue cell tumor typically characterized by an EWSR1 rearrangement and expression of CD99 and NKX2.2, without expression of hematopoietic markers such as CD45. CD43...